Start typing to search across the full knowledge system.
Canonical Source · peer reviewed study
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence context
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
Investigation
The phase II prostate trial randomized 50 and treated 47; PSA50 occurred in 13/32 (41%) with ascorbate plus docetaxel versus 5/15 (33%) with placebo plus docetaxel (p=0.44), without clear progression-free or overall survival benefit. The Results/participant-flow denominator differs from abbreviated abstract wording.
Subject families